Nicotinamide adenine dinucleotide (NAD+) is not a peptide or a drug candidate synthesized to mimic a natural signal — it is a coenzyme every human cell already makes and uses continuously to run oxidation-reduction reactions and to fuel a specific set of signaling enzymes. That makes it one of the best-characterized molecules in biochemistry at the level of basic mechanism, and one of the least well-characterized at the level of "what happens if a person raises it." The evidence has three distinct layers, kept separate here rather than blended into one story. First, the redox and enzyme biology of NAD+ is deep, decades-old, and not seriously disputed. Second, human trial data exist mostly for oral NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — and those trials reliably show the precursors raise blood NAD+ metabolites, with metabolic and functional outcome data that are mixed to null. Third, human data on administering NAD+ itself are thin: a small number of pharmacokinetic and tolerability studies, and essentially no controlled outcome trials. Readers should treat claims about direct NAD+ administration with more caution than claims about NAD+ biology in general, and should not assume a finding for NR or NMN transfers to NAD+ itself, or vice versa.
What Is NAD+?
NAD+ is a dinucleotide: two nucleotides (an adenine-containing one and a nicotinamide-containing one) joined through their phosphate groups. It exists in cells in two interconverting redox states, oxidized (NAD+) and reduced (NADH), and this pair is the single most important electron shuttle in cellular metabolism — it accepts and donates electrons in glycolysis, the TCA cycle, and oxidative phosphorylation, and a related phosphorylated pair (NADP+/NADPH) does analogous work in biosynthesis and antioxidant defense [1].
Beyond its redox role, NAD+ is also a consumed substrate — not just a shuttle — for several enzyme families central to cell regulation: the sirtuins (NAD+-dependent deacylases involved in metabolic and stress-response signaling), the PARP family (poly-ADP-ribose polymerases, central to DNA-damage repair), and CD38 and related ectoenzymes (which hydrolyze NAD+ as part of calcium signaling and immune function) [1,2]. Every one of these enzymes destroys a molecule of NAD+ to do its job, which is why NAD+ levels are not a static pool but the net output of a continuous synthesis-versus-consumption balance [2].
Cells replenish NAD+ through two routes: de novo synthesis from the amino acid tryptophan, and the "salvage pathway," which recycles nicotinamide (the byproduct left over after sirtuins, PARPs, and CD38 consume NAD+) back into new NAD+ through NMN as an intermediate. In mammals the salvage pathway carries most of the flux, and its rate-limiting step is a single enzyme, nicotinamide phosphoribosyltransferase (NAMPT), which converts nicotinamide into NMN [1,2]. This matters for the evidence below: the reason researchers study NR and NMN at all, rather than oral NAD+ directly, is that intact NAD+ is a large, charged, membrane-impermeant molecule degraded by ectoenzymes before it can be absorbed intact, whereas its smaller precursors have dedicated transporters and enter the salvage pathway directly [3]. Whether oral NAD+ itself is meaningfully bioavailable in humans has not been directly established the way it has for NR [3].
Mechanism of Action
Redox cofactor function. NAD+/NADH cycling is required for essentially all central carbon metabolism — glycolysis, the TCA cycle, fatty acid oxidation, and the electron transport chain all depend on it. This is uncontroversial, foundational biochemistry rather than a hypothesis under test [1].
Sirtuin substrate. The seven mammalian sirtuins (SIRT1–7) use NAD+ as a required cosubstrate to remove acyl groups from target proteins, a reaction that consumes NAD+ and produces nicotinamide as a byproduct. Sirtuins are implicated in mitochondrial biogenesis, metabolic gene regulation, and stress resistance in animal models, and reduced NAD+ availability is proposed to limit their activity with age [1,2].
PARP substrate and DNA repair. PARP enzymes, principally PARP1, consume NAD+ to add poly-ADP-ribose chains to proteins at sites of DNA damage. Under conditions of high genotoxic stress, PARP activation can consume a large share of the cellular NAD+ pool, which is one proposed mechanism connecting DNA damage accumulation to age-related NAD+ decline [1,2].
CD38 and NAD+ degradation. CD38 is a cell-surface and mitochondrial NADase whose expression and activity increase with age in mouse tissue. In a widely cited 2016 study, genetic deletion or pharmacological inhibition of CD38 in mice prevented the age-related decline in tissue NAD+ and the associated mitochondrial dysfunction, and CD38 was identified as a major enzyme responsible for degrading NMN itself in vivo — a finding with direct relevance to precursor supplementation, since it means CD38 activity could limit how much NMN survives to become NAD+ [4].
Net effect on aging biology. The prevailing hypothesis, laid out in influential reviews, is that a combination of rising NAD+-consuming enzyme activity (CD38, PARPs) and falling salvage-pathway output degrades the NAD+/NADH balance with age, thereby constraining sirtuin activity, mitochondrial function, and DNA repair capacity — and that restoring NAD+ availability could correct some of these deficits [1,2]. This is a coherent, well-argued model. It is still a model: demonstrating that raising NAD+ reverses the downstream consequences in humans is a separate, much harder question, addressed in the next section.
Research Findings by Area
Age-related decline: what is actually measured, and where
The claim that NAD+ "declines with age" is often stated as settled fact; the primary human data behind it are narrower than the popular framing suggests. The most-cited human tissue study measured a NAD+-related redox marker and oxidative damage markers in skin biopsies from patients aged 0–77 and found DNA damage correlated significantly with age — skin, not blood or muscle, and cross-sectional, not longitudinal [5]. Separately, rodent work established that tissue NAD+ decline is at least partly enzymatically driven, not merely a passive consequence of reduced synthesis: CD38 deletion largely prevented the age-related fall in NAD+ across multiple mouse tissues [4]. Human trials discussed below generally assume the same premise — that circulating or tissue NAD+ metabolites are lower in older or metabolically unhealthy participants — but a comprehensive, multi-tissue, longitudinal human dataset tracking NAD+ decline across the lifespan does not yet exist in the literature reviewed here.
Oral NAD+ precursor bioavailability
Because intact NAD+ has poor predicted oral bioavailability, most human intervention research has used NR or NMN instead. A pharmacokinetic study in mice and humans found that a single oral dose of NR raised human blood NAD+ by as much as 2.7-fold and demonstrated superior pharmacokinetics compared with the two other main dietary vitamin B3 forms, nicotinic acid and nicotinamide, establishing NR as reliably and uniquely orally bioavailable in a way that had not previously been shown for a NAD+ precursor [3]. This paper, more than any single study, is why the subsequent human trial literature exists.
Nicotinamide riboside (NR) human trials
A randomized, double-blind, placebo-controlled crossover trial of chronic NR supplementation in thirty healthy middle-aged and older adults found the compound well tolerated and reported raised NAD+ metabolite levels in peripheral blood mononuclear cells, without significant change in several measured cardiovascular and metabolic parameters over the trial's short duration [6]. A separate randomized, placebo-controlled eight-week safety trial in healthy overweight adults reported that NR (branded NIAGEN) dose-dependently and significantly increased whole-blood NAD+ — by 22%, 51%, and 142% across three doses — sustained over the study, with no significant difference in adverse events versus placebo [7]. In aged men, a placebo-controlled crossover trial found that three weeks of NR increased the skeletal-muscle NAD+ metabolome and shifted muscle gene-expression signatures toward an anti-inflammatory profile, without changing measured mitochondrial bioenergetics [8].
Metabolic outcome data are where the picture turns mixed. A twelve-week randomized, placebo-controlled trial in obese, insulin-resistant men reported no serious adverse events related to NR and no improvement in insulin sensitivity, endogenous glucose production, or whole-body glucose disposal — the outcomes the trial was designed to move [9]. A separate six-week randomized trial in healthy overweight or obese adults reported increases in skeletal-muscle NAD+ metabolites and minor changes in body composition and sleeping metabolic rate, but no broader metabolic benefit [10]. A 2023 review summarizing the accumulated NR human literature concluded that, despite consistent evidence NR raises NAD+ metabolites and is well tolerated, evidence for clinically meaningful physiological benefit in humans remains limited and inconsistent across trials [11].
Nicotinamide mononucleotide (NMN) human trials
NMN human data are newer and smaller in aggregate but include one widely cited positive result. In a ten-week randomized, placebo-controlled, double-blind trial, twenty-five postmenopausal women with prediabetes who were overweight or obese received daily oral NMN; insulin-stimulated glucose disposal (measured by hyperinsulinemic-euglycemic clamp) and skeletal-muscle insulin signaling increased in the NMN group but not the placebo group, and the authors reported increased muscle insulin sensitivity and remodeling with treatment [12]. A separate open-label safety and pharmacokinetic study in healthy Japanese adults reported that oral NMN administration was safe and significantly increased blood NAD+ and its metabolite NAMN [13].
Set against that, a 2024 systematic review and meta-analysis pooling eight randomized controlled trials of NMN (250–2,000 mg/day, 342 total participants, mostly non-diabetic middle-aged and older adults) found no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, insulin-resistance indices (HOMA-IR), or lipid profile across the pooled short-term trials [14]. Taken together, the NMN literature currently shows one notable positive signal in a specific population (prediabetic postmenopausal women) against a pooled null result across broader, shorter trials — a pattern that argues for treating any single positive trial as a hypothesis to be tested further, not a settled finding.
Direct NAD+ administration: the thin end of the evidence
Human data on administering NAD+ itself, rather than a precursor, are the least developed part of this literature. The most-cited study is a small pilot investigating the human plasma and urine NAD+ metabolome during a six-hour intravenous infusion of NAD+, which reported detectable rises in plasma NAD+ beginning roughly two hours after infusion start and increased urinary NAD+ concentrations by six hours [15]. This is a pharmacokinetic and tolerability report — it describes what happens to measured NAD+ and its metabolites during and shortly after an infusion in a small sample, not a controlled trial of any clinical outcome. No published, adequately powered, placebo-controlled trial measuring a functional or clinical endpoint after IV or oral NAD+ administration (as opposed to a precursor) was located for this review. A 2021 review compiling the preclinical and clinical NAD+-precursor literature likewise treats direct NAD+ pharmacokinetic data as a minor, early-stage subset of a field otherwise built on precursor studies [16].
Safety
Across the NR trials reviewed here, the compound was consistently reported as well tolerated at the doses studied, with no significant excess of adverse events versus placebo in randomized designs, and no serious safety signal identified in trials extending to twelve weeks [6,7,9]. The Okabe NMN study similarly reported no safety concerns in its human cohort [13]. These short trials do not establish multi-year safety of either precursor or direct NAD+ administration.
Limitations and Open Questions
Precursor data are not NAD+ data. The great majority of the human evidence summarized above concerns NR or NMN, not NAD+ itself. Raising blood NAD+ metabolites via a precursor is a different intervention, with different pharmacokinetics and different regulatory status, than administering NAD+ directly, and readers should not conflate the two evidence bases.
Mixed-to-null metabolic outcomes. Multiple well-designed randomized trials of NR found no improvement in insulin sensitivity or broader metabolic parameters despite confirmed increases in NAD+ metabolites [9,10], and a 2024 pooled analysis of NMN trials found no significant effect on glucose or lipid markers [14]. Raising a biomarker is not the same as producing a downstream physiological effect, and several trials designed specifically to test that link came back negative.
Short trial durations. The individual precursor trials summarized here generally lasted weeks. Their durations do not establish effects on aging processes that unfold over years, and this selected study index should not be treated as an exhaustive review of every NAD+-related intervention.
Direct NAD+ outcome evidence is limited in the cited literature. Beyond a small pharmacokinetic pilot [15], the sources reviewed here do not establish clinical benefits of direct NAD+ administration. Assertions about what direct NAD+ administration accomplishes in humans currently rest on inference from precursor studies and animal mechanism work, not on direct evidence.
Regulatory status differs by form. Direct NAD+, NR and NMN are different substances. Evidence that an oral precursor raises NAD+ metabolites does not establish approval or clinical benefit for direct NAD+ research material. Supplement marketing and drug approval are separate questions; the cited clinical studies do not determine the marketing status of a particular product.
Frequently Asked Questions
Is NAD+ the same thing as NR or NMN? No. NAD+ is the coenzyme itself. NR and NMN are smaller precursor molecules the body converts into NAD+ through the salvage pathway. Most human trial data described above involve NR or NMN, not NAD+ directly [3,6,7,12,13].
Does oral NAD+ raise blood NAD+ the way NR does? This has not been directly demonstrated in the published human literature reviewed here. The rationale for using precursors instead of NAD+ itself is that intact NAD+ is a large, charged molecule with a plausible bioavailability problem, whereas NR has demonstrated, published oral bioavailability data in humans [3].
Do human trials show NAD+-boosting compounds improve metabolic health? The results are mixed. One trial in prediabetic postmenopausal women found NMN improved insulin-stimulated glucose disposal [12], but a pooled 2024 analysis of eight NMN trials found no significant effect on glucose or lipid markers [14], and multiple NR trials found no improvement in insulin sensitivity despite raised NAD+ metabolites [9,10]. Readers should not treat any single positive trial as representative of the field.
Is there direct evidence that IV or injected NAD+ does anything in humans? The available published data are limited to a small pharmacokinetic pilot describing plasma and urine NAD+ changes during a six-hour infusion [15]. No controlled trial measuring a clinical or functional outcome after direct NAD+ administration was located for this review.
Why does NAD+ decline get attributed to CD38 and PARPs specifically? Because both enzyme families consume NAD+ as a substrate, and rodent work has shown CD38 activity rises with age and that removing CD38 prevents much of the age-related tissue NAD+ decline seen in wild-type mice [4]. PARP activation under high genotoxic stress is proposed to consume NAD+ by an analogous, if less directly demonstrated, mechanism in the aging context [1,2].
Do precursor studies establish approval for direct NAD+? No. NR and NMN trial results concern those specific interventions. They do not establish drug approval, clinical efficacy or product quality for direct NAD+ research material.
References
- Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. doi:10.1126/science.aac4854 — PMID: 26785480
- Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547. doi:10.1016/j.cmet.2018.02.011 — PMID: 29514064
- Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. doi:10.1038/ncomms12948 — PMID: 27721479
- Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. doi:10.1016/j.cmet.2016.05.006 — PMID: 27304511
- Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. doi:10.1371/journal.pone.0042357 — PMID: 22848760
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. doi:10.1038/s41467-018-03421-7 — PMID: 29599478
- Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9(1):9772. doi:10.1038/s41598-019-46120-z — PMID: 31278280
- Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728.e6. doi:10.1016/j.celrep.2019.07.043 — PMID: 31412242
- Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. doi:10.1093/ajcn/nqy132 — PMID: 29992272
- Remie CME, Roumans KHM, Moonen MPB, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr. 2020;112(2):413-426. doi:10.1093/ajcn/nqaa072 — PMID: 32320006
- Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. 2023;9(29):eadi4862. doi:10.1126/sciadv.adi4862 — PMID: 37478182
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi:10.1126/science.abe9985 — PMID: 33888596
- Okabe K, Yaku K, Uchida Y, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022;9:868640. doi:10.3389/fnut.2022.868640 — PMID: 35479740
- Chen F, Zhou D, Kong AP, Yim NT, Dai S, Chen YN, Hui LL. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Curr Diab Rep. 2024;25(1):4. doi:10.1007/s11892-024-01557-z — PMID: 39531138
- Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257. doi:10.3389/fnagi.2019.00257 — PMID: 31572171
- Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing. Mech Ageing Dev. 2021;199:111567. doi:10.1016/j.mad.2021.111567 — PMID: 34517020
This article is an educational summary of published research. It is not medical advice, and it does not describe, endorse, or recommend any use of NAD+ in humans. NAD+ is not an approved drug for any indication. NAD+ precursors (such as NR and NMN) are marketed in the United States under a separate dietary-supplement regulatory framework, distinct from the research-use framing of this page — this article does not evaluate or endorse any supplement product. Products referenced on this site are sold for laboratory research use only.
